JAC Advance Access published online on February 11, 2003
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkg123
© 2003 by The British Society for Antimicrobial Chemotherapy
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Review
1 Institute for Medical Microbiology and Epidemiology of Infectious
Diseases, University of Leipzig, Liebigstrasse 24, 04103 Leipzig,
Germany
* Corresponding author. E-mail: ackermg{at}medizin.uni-leipzig.de.
Telithromycin (HMR 3647) is the first ketolide introduced
into clinical practice. Ketolides are semisynthetic derivates of
erythromycin A that carry novel biological properties on the erythronolide A
ring. This new class of antimicrobials was designed to overcome
current resistance mechanisms against erythromycin A within Gram-positive
cocci. Ketolides do not induce macrolide-lincosamide-streptogramin
B (MLSB) resistance and are active against erythromycin
resistance methylase gene (erm)-carrying Gram-positive
cocci. This review summarizes published data on telithromycin and
intends to define the challenge that a new antimicrobial brings
to medical practice.
Keywords: new antimicrobials, telithromycin, resistance
Drugs of the 21st century: telithromycin (HMR 3647)--the
first ketolide
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. C. Kouvela, D. L. Kalpaxis, D. N. Wilson, and G. P. Dinos Distinct Mode of Interaction of a Novel Ketolide Antibiotic That Displays Enhanced Antimicrobial Activity Antimicrob. Agents Chemother., April 1, 2009; 53(4): 1411 - 1419. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Li, H. Ouellet, D. H. Sherman, and L. M. Podust Analysis of Transient and Catalytic Desosamine-binding Pockets in Cytochrome P-450 PikC from Streptomyces venezuelae J. Biol. Chem., February 27, 2009; 284(9): 5723 - 5730. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kiem and J. J. Schentag Interpretation of Antibiotic Concentration Ratios Measured in Epithelial Lining Fluid Antimicrob. Agents Chemother., January 1, 2008; 52(1): 24 - 36. [Full Text] [PDF]
|
|
|
|
|
|
A. Al-Lahham, P. C. Appelbaum, M. van der Linden, and R. R. Reinert Telithromycin-Nonsusceptible Clinical Isolates of Streptococcus pneumoniae from Europe Antimicrob. Agents Chemother., November 1, 2006; 50(11): 3897 - 3900. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Karahalios, D. L. Kalpaxis, H. Fu, L. Katz, D. N. Wilson, and G. P. Dinos On the Mechanism of Action of 9-O-Arylalkyloxime Derivatives of 6-O-Mycaminosyltylonolide, a New Class of 16-Membered Macrolide Antibiotics Mol. Pharmacol., October 1, 2006; 70(4): 1271 - 1280. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Sherman, S. Li, L. V. Yermalitskaya, Y. Kim, J. A. Smith, M. R. Waterman, and L. M. Podust The Structural Basis for Substrate Anchoring, Active Site Selectivity, and Product Formation by P450 PikC from Streptomyces venezuelae J. Biol. Chem., September 8, 2006; 281(36): 26289 - 26297. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gibreel and D. E. Taylor Macrolide resistance in Campylobacter jejuni and Campylobacter coli J. Antimicrob. Chemother., August 1, 2006; 58(2): 243 - 255. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rantala, M. Haanpera-Heikkinen, M. Lindgren, H. Seppala, P. Huovinen, J. Jalava, and the Finnish Study Group for Antimicrobial Resistan Streptococcus pneumoniae Isolates Resistant to Telithromycin. Antimicrob. Agents Chemother., May 1, 2006; 50(5): 1855 - 1858. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Johnston, F. Blasi, P. N. Black, R. J. Martin, D. J. Farrell, R. B. Nieman, and the TELICAST Investigators The Effect of Telithromycin in Acute Exacerbations of Asthma N. Engl. J. Med., April 13, 2006; 354(15): 1589 - 1600. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Rantala, S. Huikko, P. Huovinen, J. Jalava, and the Finnish Study Group for Antimicrobial Resistan Prevalence and Molecular Genetics of Macrolide Resistance among Streptococcus pneumoniae Isolates Collected in Finland in 2002 Antimicrob. Agents Chemother., October 1, 2005; 49(10): 4180 - 4184. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Lippert, S. Gbenado, C. Qiu, B. Lavin, and S. J. Kovacs The Bioequivalence of Telithromycin Administered Orally as Crushed Tablets Versus Tablets Swallowed Whole J. Clin. Pharmacol., September 1, 2005; 45(9): 1025 - 1031. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Reed, G. C Wall, N. P Shah, J. M Heun, and G. A Hicklin Verapamil Toxicity Resulting from a Probable Interaction with Telithromycin Ann. Pharmacother., February 1, 2005; 39(2): 357 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Telithromycin Journal Watch Infectious Diseases, August 9, 2004; 2004(809): 9 - 9. [Full Text]
|
|
|
|
|
|
L. Drago, E. De Vecchi, L. Nicola, A. Colombo, and M. R. Gismondo Selection of resistance of telithromycin against Haemophilus influenzae, Moraxella catarrhalis and streptococci in comparison with macrolides J. Antimicrob. Chemother., August 1, 2004; 54(2): 542 - 545. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R. Reinert Clinical efficacy of ketolides in the treatment of respiratory tract infections J. Antimicrob. Chemother., June 1, 2004; 53(6): 918 - 927. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Low, M. E. Pichichero, and U. B. Schaad Optimizing Antibacterial Therapy for Community-Acquired Respiratory Tract Infections in Children in an Era of Bacterial Resistance Clinical Pediatrics, March 1, 2004; 43(2): 135 - 151. [Abstract] [PDF]
|
|
|
|
|
|
M. R. Jacobs, S. Bajaksouzian, and P. C. Appelbaum Telithromycin post-antibiotic and post-antibiotic sub-MIC effects for 10 Gram-positive cocci J. Antimicrob. Chemother., November 1, 2003; 52(5): 809 - 812. [Abstract] [Full Text] [PDF]
|
|